| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Eagle Pharmaceuticals, Inc. (EGRX) has 0 insiders with recent SEC Form 4 filings, including 1 buy and 38 sells. EGRX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 20, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 100,000 | $82.06 | $8,206,307.87 | -0.9% | |
| Mar 9, 2017 | Pernock David | Pres. &Chief Comm. Officer | Buy | 450 | $77.84 | $35,028.49 | New | |
| Jan 4, 2017 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 65,114 | $85.16 | $5,545,108.24 | -1.7% | |
| Dec 23, 2016 | Krill Steven L. | EVP &Chief Scientific Officer | Sale+OE | 50,505 | $76.40 | $3,858,621.81 | -100% | |
| Dec 13, 2016 | Krill Steven L. | EVP &Chief Scientific Officer | Sale+OE | 10,000 | $73.62 | $736,163.00 | -100% | |
| Nov 30, 2016 | Krill Steven L. | EVP &Chief Scientific Officer | Sale+OE | 5,987 | $80.00 | $478,960.00 | -100% | |
| Nov 28, 2016 | Flaum Sander A | Director | Sell | 5,000 | $78.66 | $393,300.00 | -30.5% | |
| Nov 11, 2016 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 34,486 | $85.15 | $2,936,604.80 | -0.2% | |
| Nov 9, 2016 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 153,830 | $79.29 | $12,197,276.85 | -0.5% | |
| Nov 4, 2016 | Proquest Investments Iv, L.P. | 10% Owner | Sell | 245,770 | $71.02 | $17,455,384.89 | -1.9% |